Premium
P1‐350: HIPPOCAMPAL INTRINSIC CONNECTIVITY SUPPORTS COGNITIVE RESERVE IN AMYLOID‐POSITIVE COGNITIVELY NORMAL SUBJECTS AND ALZHEIMER'S DISEASE PATIENTS
Author(s) -
Hönig Merle C.,
Bischof Gerard N.,
Alves Isadora Lopes,
Ahlswede Mareike,
Sakagiannis Panagiotis,
Jessen Frank,
Schmidt Mark E.,
Barkhof Frederik,
Eimeren Thilo,
Drzezga Alexander
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.905
Subject(s) - cognition , neuroimaging , posterior cingulate , neuroscience , neuropsychology , hippocampal formation , amyloid (mycology) , pittsburgh compound b , resting state fmri , psychology , alzheimer's disease , cognitive reserve , medicine , disease , cognitive impairment , pathology
Methods: LEADSwill recruit and longitudinally followapproximately 400 amyloid-positive (EOAD), 100 amyloid-negative cognitively impaired subjects (EOnonAD) and 100 age-matched controls. Participants will undergo clinical and psychometric assessments, MRI, amyloid ([18F]Florbetaben) and tau ([18F]AV1451) PET, CSF, DNA, RNA, plasma, serum and peripheral blood mononuclear cells collection at three time points. Methods are harmonized with ADNI and DIAN to facilitate scientific comparisons.Results: LEADSenrollment is ongoing. Demographics of the current sample are shown in Table. Figure1 presents mean hippocampal volume as well as the mean entorhinal and precuneal cortical thickness in the 17 CN, 12 EOAD and 6 EOnonAD with available MRI data. Group comparisons projected on Freesusrfer-rendered 3D brain hemispheric models can be seen in Figure 2. Figure 3 presents the mean global amyloid PET SUVR and Figure 4 the mean tau PET deposition by early-, midand late-stage Braak regions in 13 CN, 11 EOAD, 6 EOnonAD with both amyloid and tau PET data availability. The latest enrollment and study participant updates will be presented at the meeting. Conclusions: LEADS will develop a publicly available natural history biomarker and clinical data set in EOAD and will enable future planning and implementation of clinical trials in EOAD. Successful completion of this project will address several substantial gaps in our understanding of EOAD and AD research in general.